7.6395
前日終値:
$7.73
開ける:
$7.72
24時間の取引高:
214.14K
Relative Volume:
1.30
時価総額:
$163.21M
収益:
$66.59M
当期純損益:
$-104.93M
株価収益率:
-1.5433
EPS:
-4.95
ネットキャッシュフロー:
$-96.48M
1週間 パフォーマンス:
+16.08%
1か月 パフォーマンス:
+6.55%
6か月 パフォーマンス:
+47.68%
1年 パフォーマンス:
-47.89%
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
名前
Enanta Pharmaceuticals Inc
セクター
電話
617 607 0800
住所
4 KINGSBURY AVENUE, WATERTOWN, MA
ENTA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
ENTA
Enanta Pharmaceuticals Inc
|
7.635 | 148.78M | 66.59M | -104.93M | -96.48M | -4.95 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
468.64 | 121.30B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
555.46 | 61.60B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
325.17 | 41.17B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
573.49 | 34.35B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
294.06 | 27.29B | 3.81B | -644.79M | -669.77M | -6.24 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2023-08-09 | ダウングレード | JP Morgan | Neutral → Underweight |
2023-08-08 | ダウングレード | Jefferies | Buy → Hold |
2022-12-09 | 開始されました | H.C. Wainwright | Buy |
2022-07-06 | アップグレード | Evercore ISI | In-line → Outperform |
2022-06-01 | アップグレード | Evercore ISI | Underperform → In-line |
2021-10-07 | 開始されました | Jefferies | Buy |
2021-09-09 | 開始されました | SVB Leerink | Mkt Perform |
2021-01-29 | アップグレード | JP Morgan | Underweight → Neutral |
2020-11-24 | 開始されました | Evercore ISI | Underperform |
2020-08-28 | 再開されました | ROTH Capital | Buy |
2020-08-26 | 開始されました | Piper Sandler | Overweight |
2020-07-27 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
2020-03-17 | アップグレード | Robert W. Baird | Neutral → Outperform |
2019-11-22 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2019-09-26 | ダウングレード | JP Morgan | Neutral → Underweight |
2019-05-24 | 開始されました | Wolfe Research | Outperform |
2019-04-23 | アップグレード | Berenberg | Hold → Buy |
2018-12-13 | 開始されました | Berenberg | Hold |
2018-06-06 | 開始されました | ROTH Capital | Buy |
2018-02-08 | ダウングレード | JP Morgan | Overweight → Neutral |
2018-01-02 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
2017-11-21 | 繰り返されました | RBC Capital Mkts | Outperform |
2017-09-15 | 開始されました | RBC Capital Mkts | Outperform |
2017-07-11 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
2016-04-28 | ダウングレード | JMP Securities | Mkt Outperform → Mkt Perform |
2016-02-09 | 繰り返されました | Barclays | Underweight |
2015-10-23 | ダウングレード | Barclays | Equal Weight → Underweight |
2015-10-23 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
すべてを表示
Enanta Pharmaceuticals Inc (ENTA) 最新ニュース
What analysts say about Enanta Pharmaceuticals Inc. stockStrong return on investment - PrintWeekIndia
What drives Enanta Pharmaceuticals Inc. stock priceFree Investment Case Studies - Autocar Professional
Is Enanta Pharmaceuticals Inc. a good long term investmentSuperior profit margins - jammulinksnews.com
Enanta Pharmaceuticals Inc. Stock Analysis and ForecastDynamic profit opportunities - jammulinksnews.com
why enanta pharmaceuticals inc. stock attracts strong analyst attentionShort Term Risk Controlled Alerts - Newser
Will Enanta Pharmaceuticals Inc. stock benefit from interest rate changesFast Growing Stocks - Newser
Enanta Pharmaceuticals to Participate in Baird’s Biotech Discovery Series - BioSpace
how enanta pharmaceuticals inc. stock performs during market volatilityFree Smart Investment Opportunities - Newser
What makes Enanta Pharmaceuticals Inc. stock price move sharplyBreakout Momentum Stocks - Newser
How Enanta Pharmaceuticals Inc. stock performs during market volatilityFree Investment Community - Newser
Why Enanta Pharmaceuticals Inc. stock attracts strong analyst attentionVolume Spike Monitors - Newser
(ENTA) On The My Stocks Page - news.stocktradersdaily.com
Enanta Pharmaceuticals Insider Buyers Net US$65k Despite 11% Stock Decline - simplywall.st
(ENTA) Technical Pivots with Risk Controls - news.stocktradersdaily.com
Enanta Pharmaceuticals’ SWOT analysis: stock shifts focus to immunology amid RSV progress - Investing.com Nigeria
AbbVie Secures FDA Approval to Expand Mavyret’s Label - Yahoo Finance
ENTA’s Market Quandary: Decoding the Ups and Downs of 2023 - investchronicle.com
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga
FDA Expands AbbVie's Mavyret Label To Include Acute Hepatitis C Treatment (CORRECTED) - Benzinga
AbbVie wins FDA nod for Mavyret label expansion (ABBV:NYSE) - Seeking Alpha
Enanta Pharmaceuticals' Partner AbbVie Receives U.S. FDA Approva - GuruFocus
Enanta Pharmaceuticals’ Partner AbbVie Receives U.S. FDA Approval of an Expanded Indication for MAVYRET® (glecaprevir/pibrentasvir) as the First and Only Treatment for People with Acute Hepatitis C Virus - Yahoo Finance
(ENTA) Proactive Strategies - news.stocktradersdaily.com
Enanta Pharmaceuticals (NASDAQ:ENTA) Given New $24.00 Price Target at JMP Securities - Defense World
Enanta Pharma (ENTA) Receives Target Price Boost from JMP Securi - GuruFocus
Enanta (ENTA) Price Target Raised as Key Clinical Results Antici - GuruFocus
Enanta (ENTA) Price Target Raised as Key Clinical Results Anticipated | ENTA Stock News - GuruFocus
Citizens JMP raises Enanta Pharmaceuticals stock price target to $24 By Investing.com - Investing.com UK
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference - BioSpace
Enanta Pharmaceuticals to Present at the Jefferies Global Health - GuruFocus
Enanta Pharmaceuticals to Present at the Jefferies Global Healthcare Conference | ENTA Stock News - GuruFocus
Enanta Pharmaceuticals Inc (ENTA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):